Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases
Cartesian Therapeutics has entered a strategic licensing agreement with WestGene Biopharma to develop in vivo CAR-T therapies for autoimmune diseases. The partnership combines Cartesian’s mRNA payloads, specifically from its lead asset Descartes-08, with WestGene’s targeted lipid nanoparticle (tLNP) delivery platform. A Phase 1 dose-escalation study in patients with generalized myasthenia gravis is expected to initiate in the second half of 2026, with clinical data anticipated in the first half of 2027.
Key figures
- Drug Name
- Descartes-08
- Phase Of Trial
- Phase 1
- Data readout
- 1H 2027
- Upfront payment
- Yes (amount not disclosed)
- Clinical initiation
- 2H 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.